# GEMCAD-REVEAL STUDY - Circulating Tumor DNA as a Predictor of Relapse in Patients With Locally Advanced Rectal Cancer.

> **NCT05674422** · — · ACTIVE_NOT_RECRUITING · sponsor: **Grupo Espanol Multidisciplinario del Cancer Digestivo** · enrollment: 120 (estimated)

## Conditions studied

- Patients With Locally Advanced Rectal Cancer

## Interventions

- **DRUG:** total neoadjuvant therapy

## Key facts

- **NCT ID:** NCT05674422
- **Lead sponsor:** Grupo Espanol Multidisciplinario del Cancer Digestivo
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-26
- **Primary completion:** 2025-04-26
- **Final completion:** 2026-07
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05674422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05674422, "GEMCAD-REVEAL STUDY - Circulating Tumor DNA as a Predictor of Relapse in Patients With Locally Advanced Rectal Cancer.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05674422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*